Phathom Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending September 29, 2021 was -35.55% (a -178.39% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -115.6%
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 381.73% (a -99.62% decrease from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending September 29, 2021 was 45.15% (a -64.95% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -88.17% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
45.15% 128.83% 187.25% 381.73%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of Phathom Pharmaceuticals, Inc.

Most recent Research and Development (R&D) Expenses Growthof PHAT including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -35.55% 45.35% 29.72%
2020 227.88% 476.64% 436.04% 3598.14% 381.73%
2019 211633.33% 101770.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.